US Patent

US12303592 — Formulations for parenteral delivery of compounds and uses thereof

Method of Use · Assigned to Wyeth LLC · Expires 2027-08-03 · 1y remaining

Vulnerability score 88/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects formulations for delivering methylnaltrexone compositions to prevent or reduce side effects from analgesic opioids.

USPTO Abstract

The present invention provides formulations that achieve effective delivery of methylnaltrexone compositions. The provided formulations are useful for preventing, treating delaying, diminishing or reducing the severity of side effects resulting from use of analgesic opioids.

Drugs covered by this patent

methylnaltrexone-bromide (METHYLNALTREXONE BROMIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4197`	—	methylnaltrexone-bromide
`U-4197`	—	methylnaltrexone-bromide
`U-4197`	—	methylnaltrexone-bromide

Patent Metadata

Patent number: US12303592
Jurisdiction: US
Classification: Method of Use
Expires: 2027-08-03
Drug substance claim: No
Drug product claim: Yes
Assignee: Wyeth LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.